Impact BioMedical (IBO) Q1 2026 Earnings
IBO·Reported May 12, 2026·Before market open
Impact BioMedical reported Q1 2026 revenue of $7.0K. Diluted EPS came in at $-0.02 (+81.8% YoY).
Revenue
$7.0K
Diluted EPS
$-0.02
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Impact BioMedical's Q1 2026 earnings report.
Impact BioMedical (IBO) reported Q1 2026 earnings on May 12, 2026 before market open.
Impact BioMedical reported revenue of $7.0K and diluted EPS of $-0.02 for Q1 2026.
Compared to the same quarter a year prior, diluted EPS grew 81.8% from $-0.11.
You can read the 10-Q periodic report (0001493152-26-022512) directly on SEC EDGAR. The filing index links above go to sec.gov.